Radiation Necrosis
9
2
2
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
11.1%
1 terminated out of 9 trials
85.7%
-0.8% vs benchmark
11%
1 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
REMASTer: REcurrent Brain Metastases After SRS Trial
Hyperbaric Oxygen Therapy for Treatment of Severe Radiation-Induced Complications
Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis
Laser Ablation After Stereotactic Radiosurgery
Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)
The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors
Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis
Differentiation of Pseudoprogression and True Progression Through High Field Susceptibility Weighted Imaging and R2*